MARKET

KURA

KURA

Kura Oncology
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.37
+0.20
+1.64%
After Hours: 12.37 0 0.00% 16:00 02/20 EST
OPEN
12.17
PREV CLOSE
12.17
HIGH
12.42
LOW
11.87
VOLUME
171.04K
TURNOVER
--
52 WEEK HIGH
21.42
52 WEEK LOW
11.41
MARKET CAP
560.54M
P/E (TTM)
-8.0649
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of KURA and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

KURA News

  • Kura Oncology to Participate in Three Upcoming Investor Conferences
  • GlobeNewswire.1d ago
  • Kura Oncology to Report Fourth Quarter and Full Year 2019 Financial Results
  • GlobeNewswire.2d ago
  • The Pros And Cons Of Kura Oncology
  • Seeking Alpha - Article.02/04 19:04
  • The Daily Biotech Pulse: Acceleron's Positive Data Readout, Surface Oncology Gets Nod For Pushing 2 Antibodies Into Clinics
  • Benzinga.01/28 14:03

More

Industry

Biotechnology & Medical Research
-0.11%
Pharmaceuticals & Medical Research
-0.42%

Hot Stocks

Name
Price
%Change

About KURA

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small molecule product candidates that targets cell-signaling pathways, which drives the progression of certain cancers. It is developing its lead product candidate, tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. It is advancing KO-947, a small molecule inhibitor of extracellular-signal-regulated kinase (ERK), as a treatment for patients with tumors that have mutations in or other dysregulation of the mitogen-activated protein kinase (MAPK), signaling pathway, including pancreatic cancer, colorectal cancer, non-small cell lung cancer (NSCLC) and melanoma.
More

Webull offers Kura Oncology Inc (KURA) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.